🇺🇸 FDA
Patent

US 12338437

OPA1 antisense oligomers for treatment of conditions and diseases

granted A61KA61K31/7088A61K31/7125

Quick answer

US patent 12338437 (OPA1 antisense oligomers for treatment of conditions and diseases) held by STOKE THERAPEUTICS, INC. expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
STOKE THERAPEUTICS, INC.
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/7088, A61K31/7125, A61K45/06, A61K9/0048